Harmony's ARGUS Dravet Trial Enrolls to 150 After Six-Year Slip to 2027
The Phase 3 study has moved its primary completion date seven times and grown enrollment 525%, leaving the 1H 2027 readout window resting on an operationally unstable protocol.
Executive Summary
- Harmony Biosciences guided to topline Phase 3 ARGUS data for EPX-100 in Dravet syndrome in 1H 2027, a window it reaffirmed across two disclosures in early 2026 Press ReleasePress ReleaseJan 12, 2026. No endpoint data exists yet to evaluate.
- The trial's primary completion date has moved seven times since 2020, from 2021-10-01 to 2027-04-01, and enrollment has grown 525% from an original 24 participants to 150. That pattern changes how much confidence a reader should place in the current window holding.
- No other HRH1-targeted therapy is being tested in Dravet syndrome, and EPX-100 has zero head-to-head or comparator-arm competitors in the registry. That leaves the readout without a direct mechanistic benchmark.
- The dossier has no disclosed primary endpoint threshold, effect-size target, or safety profile for the US registrational analysis, only the EU outcome measure of percent change in countable motor seizures. That absence limits what conclusions the eventual readout can support.
- The catalyst is real and unresolved, but its evidentiary value depends on whether the trial's operational instability resolves into a clean dataset or another delay.
The catalyst
Harmony Biosciences said it anticipates topline data from the Phase 3 ARGUS study of EPX-100 (clemizole hydrochloride) in Dravet syndrome in the first half of 2027, guidance the company gave in a January 2026 press release and repeated in a February 2026 update Press ReleasePress ReleaseJan 12, 2026. The trial, NCT04462770, is registrational and remains in Recruiting status as of the source's last modification on 2026-06-30. The company's broader message that week centered on WAKIX, its pitolisant franchise, which it said generated approximately $868 million in net product revenue for full-year 2025 and is projected to exceed $1 billion in 2026 Press ReleasePress ReleaseJan 12, 2026. "With WAKIX on track to achieve revenue of over $1 billion in narcolepsy in 2026, Harmony is entering its next phase of growth with momentum," said Jeffrey M. Dayno, M.D., President and CEO of Harmony Biosciences Press ReleasePress ReleaseJan 12, 2026.
What the record shows
The registry history for NCT04462770 tells a story of sustained delay. The primary completion date has moved from an original 2021-10-01 target to 2022-10-01, then 2022-09-01, 2024-12-01, 2024-12-19, 2026-04-01, and most recently 2027-04-01, a cumulative delay near 2,447 days according to the trial's risk assessment. Enrollment has grown in parallel, from 24 participants at trial start to 56, 60, 100, and 150 as of May 2025. The trial briefly changed status to Completed on 2024-01-08 before reverting to Recruiting two weeks later on 2024-01-23, alongside another completion-date extension. Protocol stability tooling labels the trial's registry-change pattern "Moderate," with 2.01 change events per year across 10 tracked events, while flagging this as a proxy metric rather than confirmed amendment data.
What's missing
The dossier contains no primary endpoint threshold for the US registrational analysis, no effect-size target, no comparator arm data, and no safety profile. ClinicalTrials.gov shows no results posted for NCT04462770. The only outcome measure on record is the European Union primary outcome, percent change in countable motor seizures per 28 days during the maintenance period relative to baseline, which may or may not match the endpoint used for a US regulatory filing. Without that detail, no endpoint-met probability can be responsibly assigned.
The competitive frame
No other therapy targeting the histamine H1 receptor is in development for Dravet syndrome, and EPX-100 has zero comparator or head-to-head trials in the registry. The nearest same-indication precedents, fenfluramine (UCB Pharma), soticlestat (Takeda), and lorcaserin (Eisai), work through different serotonin-pathway or CYP46A1 mechanisms, so they inform the indication's regulatory and efficacy bar but not EPX-100's specific biology. The Dravet syndrome trial landscape includes 8 active studies, mostly early-phase, with only one other Phase 3 program, Longboard Pharmaceuticals' bexicaserin, which targets a different serotonin receptor subtype. EPX-100 carries FDA Orphan Drug and Rare Pediatric Disease designations for Dravet syndrome, statuses that reflect the disease's rare, high-unmet-need classification rather than a predictor of trial success.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.